7.6. Genetics of Solid Tumours 1655-LekM5ONKGEN-J

(in Polish) 1. The workload related to the classes requiring the direct participation of academic teachers is: - participation in lectures: 8 hours - participation in seminars: 10 hours - participation in exercises: 6 hours - consultation: 1 hour - completion of the test: 1 hour The workload related to the activities requiring the direct participation of academic teachers amounts to 26 hours, corresponding to 1.04 ECTS points 2. Balance of student workload: - participation in lectures: 8 hours - participation in seminars: 10 hours -participation in exercises: 6 hourse - consultation: 1 hour - preparation for the seminar (including reading the indicated literature): 1.5 hours - preparation for exercises (including reading the indicated literature): 1..5 hours - preparation for passing and passing: 9 + 0.5 = 9.5 hours The total student workload is 13.5 hours, which corresponds to 0.54 ECTS points 3. 3. Workload related to the conducted research - reading the indicated scientific literature: 3 hours, taking into account the results of scientific research conducted at the Department of Genetics and Molecular Oncology of the Oncology Center - participation in lectures: 6 hours - participation in seminars: 10 hours - participation in exercises: 6 hours - consultation: 1 hour The total student workload related to the conducted research is 26 hours, which corresponds to 1.04 ECTS points 4. Time required to prepare and participate in the assessment process: - preparation for exercises and seminar: 1.5 hours - preparation for passing and passing: 1.5 + 1 = 2.5 hours - 4 hours (0.16 ECTS points) 5. Balance of the student's workload of a practical nature: - participation in exercises: 6 hours - participation in seminars: 10 hours The total amount of student work of a practical nature is 16 hours, which corresponds to 0.64 ECTS points 6. Time required for compulsory practice: not applicable

(in Polish) W1: (A) Discuss the molecular and genetic processes leading to the development of malignant tumors and hereditary human tumours; (B) Lists hereditary cancer risk syndromes (C.W7, C.W9). W2. Presents personalized oncology (C.W7, C.W9, C.W.41). W3. Characterizes genetic and epigenetic biomarkers in oncology; (C.W7, C.W9, C.W.41, E.W.24). W4. Discusses international quality assessments of genetic testing; knows the basic problems of the pre-laboratory and post-laboratory phase of testing (including: non-analytical factors affecting the reliability of laboratory test results). (C.W7, C.W.9. E.W.39). W5. Discusses hereditary human cancers; standard and modern diagnostic methods used in the genetic laboratory, including early detection of constitutive changes in families with a high hereditary risk of malignant tumors; indicates international standards for interpreting sequencing results for constitutive changes. (C.W7, C.W9, E.W.24). W6.Discuss standard and modern diagnostic methods used in the genetic laboratory, including prognostic and predictive factors for therapies used in oncology, with particular emphasis on molecularly targeted therapies (C.W7, C.W9, C.W.41, C.W.42, E.W.26). W7.Introduces the latest technologies as tools in oncology, including (A) NGS [Next Generation Sequencing: fresh vs archived material; detection and interpretation of changes, multi-gene panels; international standards for the interpretation of next-generation sequencing results for somatic lesions.) and (B) liquid biopsy; (E.W.26, ). W8: Recreates the diagnostic algorithm for (A) oncological patients (B) families of high hereditary cancer risk. It defines the role and place of the oncologist, geneticist and diagnostic molecular biologist in genetic oncology diagnostics. Familiarization with the current aspects of genetic research in selected drug programs and ministerial programs. Discussion of the need to validate and standardize diagnostic tests. Emphasizing the role and necessity of screening tests in oncology, including genetic tests (C K_W40, C K_W41, E K_W24, E K_W26,).

(in Polish) Student: U1. Correctly distinguishes examinations in the detection of somatic versus constitutive changes; distinguishes between constitutive changes and acquired changes, including changes associated with the acquisition of drug resistance by cancer cells (C.U3). U2. He knows the algorithm of proceeding in the study of acquired changes in oncological patients (molecular cytogenetics and molecular genetics) versus constitutive changes in families of high, hereditary risk of malignant tumors. Makes decisions about the need to perform genetic tests (C.U3) identifies indications for tests for acquired or constitutive changes in the field of oncogenetics), (E.U16, C.U3). U3. Knows the functioning of the genetic diagnostic laboratory, starting from the acceptance of the material by the molecular methodology of the performed tests and ending with the issuance of the genetic test result. (C.U3, E.U16, E.U28) U4. He learns about the latest achievements in the field of molecular and genetic processes leading to the development of malignant tumors and hereditary human tumours. Able to assess the diagnostic value of tests and their usefulness in the diagnostic process. (E.U24) U5. He knows the international standards for interpreting the results of next-generation sequencing (I-V scale). Interprets the results of genetic tests of constitutive changes. Identifies indications for carrying out the mutation carrier test of the tested gene in other family members. interprets genetic results of changes interprets genetic results of constitutive and acquired changes in oncology using current guidelines for innovative technologies, including next generation sequencing (C.U3, E.U24) U6. He knows the international standards for interpreting the results of next-generation sequencing from cancer tissue (scale I-IV). Interprets the results of changes and makes further decisions related to the assessment of somatic or constitutive changes. Interprets genetic results of constitutive and acquired changes in oncology using current guidelines for innovative technologies, including next generation sequencing (E.U24).

(in Polish) K_K06. implementing the principles of professional camaraderie and cooperation in a team of specialists, including representatives of other medical professions, also in a multicultural and multinational environment K_K07. noticing and recognizing one's own limitations and making self-assessment of educational deficits and needs

(in Polish) Lectures: • informative lecture with the possibility of discussion Seminars: • seminars and multimedia presentations Exercises: • subject exercises • case analysis and interpretation of genetic results (constitutive changes) • case analysis and interpretation of genetic results (somatic changes)

- participatory lecture
- problem-based lecture

- seminar
- case study
- practical
- observation

(in Polish) A student commencing education in the field of cancer genetics should have knowledge of the basics of medical genetics and molecular biology

Additional information (registration calendar, class conductors, localization and schedules of classes), might be available in the USOSweb system:

• Description of 1655-LekM5ONKGEN-J in USOSweb